YOU ARE HERE:
Pharmacokinetics news
page  of 4
 
Headline
Date
  Once-a-day etravirine should work as first-line treatment
16.11.08
  One in five Kenyan patients suffers major interactions with HIV drugs
13.11.08
  Starting HIV treatment soon after a patient is diagnosed with cryptococcal meningitis decreases risk of death
03.11.08
  Plasma concentrations of rifampicin may be too low in children using currently recommended doses
31.10.08
  Heat-stable ritonavir tablet equivalent to soft gel capsule; may be approved next year
15.08.08
  Gilead now testing ritonavir replacement in human studies
23.07.08
  Nucleoside levels in seminal fluid higher than in blood, but not inside cells
18.06.08
  Combining rifampicin with increased doses of lopinavir/ritonavir tablets leads to dangerous increases in liver enzymes
13.05.08
  BHIVA: Concerns over confidentiality, drug interactions, communication, barriers to integrating GPs into HIV care
02.05.08
  Unexpected drug interaction found between Kaletra and rosuvastatin
17.04.08
  CROI: TDM-based PI dose escalation shows modest benefit in black and Hispanic, but not Caucasian, treatment-experienced patients
06.02.08
  Kaletra monotherapy studies yield conflicting results
28.01.08
  Etravirine (TMC125, Intelence) granted accelerated approval in US
21.01.08
  Interaction between efavirenz and phenytoin can result in undetectable blood levels of efavirenz
03.01.08
  Failure to suppress viral load more likely with nevirapine than efavirenz if ART started during TB treatment
19.11.07
  EACS: Once-a-day Kaletra can be risky
29.10.07
  ICAAC: No drug interactions found between TMC125 and ritonavir-boosted elvitegravir
21.09.07
  ICAAC: In NNRTI-based regimens, stepwise discontinuation minimises risk of antiretroviral resistance
19.09.07
  IAS: Studies present reassuring data on the use of ART in patients on TB treatment
23.07.07
  IAS: Botswanan study finds low concentrations of TB drugs common in HIV-positives, predict TB treatment failure
23.07.07

page  of 4